Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Venetoclax in combination with hypomethylating agents shows promising activity in Acute Myeloid Leukemia with late relapse post allogeneic stem cell transplant: From the EBMT acute leukemia working party

Blood (2025) 146 (Supplement 1): 6079.

https://doi.org/10.1182/blood-2025-6079

Published: 2025

Journal Articles

Real world outcomes of FLT3 inhibitors and hypomethylating agents as post transplant prophylaxis in Acute Myeloid Leukemia patients transplanted in first complete remission: From the EBMT acute leukemia working party

Blood (2025) 146 (Supplement 1): 4279.

https://doi.org/10.1182/blood-2025-4279

Published: 2025

Journal Articles

Allogeneic stem cell transplantation with post-transplantation cyclophosphamide in patients with acute myeloid leukemia achieving first complete remission after one versus two inductions: A study from the ALWP/EBMT

Blood (2025) 146 (Supplement 1): 4288.

https://doi.org/10.1182/blood-2025-4288

Published: 2025

Journal Articles

Validation of measurable residual disease as a surrogate endpoint in acute myeloid leukemia: A HARMONY Alliance study of European randomized trials

Blood (2025) 146 (Supplement 1): 343.

https://doi.org/10.1182/blood-2025-343

Published: 2025

Journal Articles

Independent, international validation of the unsupervised harmony classification of Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 451.

https://doi.org/10.1182/blood-2025-451

Published: 2025

Journal Articles

Autologous stem cell transplantation versus consolidation chemotherapy as post-remission treatment in newly diagnosed favorable and intermediate risk patients with AML: A comparative analysis of HOVON-SAKK-Nordic trials

Dimitrios Kotsos, Carin Hazenberg, Thomas Pabst, Patrycja Gradowska, Markus Manz, Johan Maertens, Carlos Graux, Marie-Christiane Vekemans, Bjorn Gjertsen, Soren Lehmann, Catharina Van Elssen, Peter Valk, Edo Vellenga, Gert J. Ossenkoppele, Bob Lowenberg, Marc Raaijmakers, Gerwin A. Huls, Jurjen Versluis

Blood (2025) 146 (Supplement 1): 2517.

https://doi.org/10.1182/blood-2025-2517

Published: 2025

Journal Articles

The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+ acute myeloid leukemia treated with intensive chemotherapy

Sarah Bertoli, Niklas Landberg, Emilie Bérard, Camille Gondran, Laetitia Largeaud, Véronique De Mas, Pierre-Yves Dumas, Arnaud Pigneux, Audrey Bidet, Sylvain Garciaz, Ludovic Gabellier, Gabrielle Roth-Guepin, Corentin Orvain, Pierre Peterlin, Rudy Birsen, Magda Alexis, Martin Carre, Emmanuelle Tavernier, Marion Boissard Simonet, Chantal Himberlin, Marc Maynadié, Kamel Laribi, Cécile Moluçon-Chabrot, Amine Belhabri, Samy Chraibi, Quentin Cabrera, Delphine Lebon, Emmanuel Raffoux, Thomas Cluzeau, Jean-Baptiste Micol, Mathieu Leclerc, Céline Berthon, Herve Dombret, Gunnar Juliusson, Anna Robelius, Sören Lehmann, Martin Jädersten, Lovisa Wennström, Pau Montesinos, Carmen Botella, Juan Miguel Bergua Burgues, Raimundo Garcia, Josefina Serrano, Mariluz Amigo, Patricia Garcia Ramirez, Claudia Sossa, Juan Manuel Alonso-Dominguez, Hartmut Döhner, Konstanze Döhner, Daniela Späth, Michael Kühn, Claudia Lengerke, Hans-Jörg Tischler, Christoph Röllig, Leo Ruhnke, Christian Thiede, Andreas Burchert, Hubert Serve, Carsten Mueller-Tidow, Claudia Baldus, Jurjen Versluis, Peter Valk, Daniel Kristensen, Anne Stidsholt Roug, Jiri Mayer, Mika Kontro, Pia Ettala, Vladimir Lazarevic, Christian Recher

Blood (2025) 146 (Supplement 1): 991.

https://doi.org/10.1182/blood-2025-991

Published: 2025

Journal Articles

Ptcy Overcomes HLA Mismatch in Unrelated Donor Transplant for Acute Lymphoblastic Leukemia: A Study from the ALWP of the EBMT

Blood (2024) 144 (Supplement 1): 3570.

https://doi.org/10.1182/blood-2024-205455

Published: 2024

Journal Articles

Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation in First Remission: On Behalf of the EBMT Acute Leukemia Working Party

Blood (2024) 144 (Supplement 1): 851.

https://doi.org/10.1182/blood-2024-201380

Published: 2024

Journal Articles

DNMT3A Mutations Deregulate the DNA Demethylation Pathway in Acute Myeloid Leukemia

Sanne Massaar, Emma Boertjes, Annelieke Zeilemaker, Jolinda Konijnenburg, Francois Kavelaars, Melissa Rijken, Tim Grob, Jurjen Versluis, Bob Lowenberg, Peter J. M. Valk, Mathijs Arnoud Sanders

Blood (2024) 144 (Supplement 1): 2718.

https://doi.org/10.1182/blood-2024-209821

Published: 2024

Journal Articles

Prognostic Impact of t(9;11) and Del(7q) As Intermediate-Risk Abnormalities in AML Following Allo-Transplant: Insights from the ELN 2022 Classification - an EBMT ALWP Study

Blood (2024) 144 (Supplement 1): 4945.

https://doi.org/10.1182/blood-2024-204824

Published: 2024

Journal Articles

Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMT

Blood (2024) 143 (24): 2534–2543.

https://doi.org/10.1182/blood.2023023697

Published: 2024

Includes: Supplemental data

Journal Articles

Mismatched Unrelated Donor Transplantation with Ptcy-Based Gvhd Prophylaxis Is Associated with Better Survival Than Double Unit Umbilical Cord Blood Transplantation in Patients with AML in First CR: A Study from the ALWP of the EBMT

Frederic Baron, Myriam Labopin, Jurjen Versluis, Jan Vydra, Peter A. Von Dem Borne, Emma Nicholson, Didier Blaise, Stephen Robinson, Jr., Aleksandr Kulagin, Sr., Claude-Éric Bulabois, Montserrat Rovira, Patrice Chevallier, Édouard Forcade, Jenny Louise Byrne, Jaime Sanz Caballer, Annalisa Ruggeri, Mohamad Mohty, Fabio Ciceri

Blood (2023) 142 (Supplement 1): 2233.

https://doi.org/10.1182/blood-2023-186293

Published: 2023

Journal Articles

Outcome of Allogeneic Stem Cell Transplantation in FLT3-TKD-Mutated AML - a Study on Behalf of the Acute Leukemia Working Party of the EBMT

Thomas Heinicke, Myriam Labopin, Didier Blaise, Jaime Sanz, Ibrahim Yakoub-Agha, Thomas Cluzeau, Marco Ladetto, Jürgen Finke, Eric Deconinck, Jurjen Versluis, Urpu Salmenniemi, Andreas Neubauer, Eolia Brissot, Ali Bazarbachi, Arnon Nagler, Jordi Esteve, Fabio Ciceri, Mohamad Mohty

Blood (2023) 142 (Supplement 1): 4976.

https://doi.org/10.1182/blood-2023-174233

Published: 2023

Journal Articles

Comparative Study for Haplo, MSD and MUD Allo-Hcts for AML Patients with KMT2A Rearrangement: A Study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Blood (2023) 142 (Supplement 1): 660.

https://doi.org/10.1182/blood-2023-185557

Published: 2023

Journal Articles

Encouraging Outcome of AML with t(8;16) Following Allogeneic Stem Cell Transplantation in First Remission - a Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT

Ann-Kristin Schmälter, Myriam Labopin, Jurjen Versluis, Maria Pilar Gallego Hernanz, Matthias Eder, Peter A. Von Dem Borne, Gerard Socié, Patrice Chevallier, Edouard Forcade, Andreas Neubauer, Frederic Baron, Ali Bazarbachi, Gesine Bug, Arnon Nagler, Christoph Schmid, Jordi Esteve, Fabio Ciceri, Mohamad Mohty

Blood (2023) 142 (Supplement 1): 3610.

https://doi.org/10.1182/blood-2023-182834

Published: 2023

Journal Articles

Outcome of Intensively Treated Elderly AML Patients Reported to the Harmony Alliance Compares Well to Outcome of Control Patients of the Prospective Randomized HOVON 103 Study in Elderly AML

Blood (2023) 142 (Supplement 1): 2854.

https://doi.org/10.1182/blood-2023-186277

Published: 2023

Journal Articles

CNS Prophylaxis in Adult ALL Patients after Stem Cell Transplantation: An EBMT Survey on General Practice

Blood (2023) 142 (Supplement 1): 7049.

https://doi.org/10.1182/blood-2023-182831

Published: 2023

Journal Articles

Should the European Leukemia Net 2022 Adverse Risk Classification of NPM1 mutated Acute Myeloid Leukemia be Revisited? Among Adverse Risk Cytogenetics, Solely Complex Karyotype Is Associated with Worse Post-Transplant Survival: A Study from the EBMT Acute Leukemia Working Party

Nour Moukalled, Myriam Labopin, Jurjen Versluis, Gerard Socié, Didier Blaise, Urpu Salmenniemi, Alessandro Rambaldi, Tobias Gedde-Dahl, Eleni Tholouli, Nicolaus Kröger, Jean-Henri Bourhis, Peter A. Von Dem Borne, Etienne Daguindau, Édouard Forcade, Arnon Nagler, Jordi Esteve, Fabio Ciceri, Ali Bazarbachi, Mohamad Mohty

Blood (2023) 142 (Supplement 1): 4987.

https://doi.org/10.1182/blood-2023-185434

Published: 2023

Journal Articles

Practice Patterns of Transplant Centers Regarding Maintenance Treatment Post Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia: A Survey on Behalf of the EBMT Acute Leukemia Working Party

Blood (2023) 142 (Supplement 1): 7089.

https://doi.org/10.1182/blood-2023-187095

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Venetoclax in combination with hypomethylating agents shows promising activity in Acute Myeloid Leukemia with late relapse post allogeneic stem cell transplant: From the EBMT acute leukemia working party

Real world outcomes of FLT3 inhibitors and hypomethylating agents as post transplant prophylaxis in Acute Myeloid Leukemia patients transplanted in first complete remission: From the EBMT acute leukemia working party

Allogeneic stem cell transplantation with post-transplantation cyclophosphamide in patients with acute myeloid leukemia achieving first complete remission after one versus two inductions: A study from the ALWP/EBMT

Validation of measurable residual disease as a surrogate endpoint in acute myeloid leukemia: A HARMONY Alliance study of European randomized trials

Independent, international validation of the unsupervised harmony classification of Acute Myeloid Leukemia

Autologous stem cell transplantation versus consolidation chemotherapy as post-remission treatment in newly diagnosed favorable and intermediate risk patients with AML: A comparative analysis of HOVON-SAKK-Nordic trials

The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+ acute myeloid leukemia treated with intensive chemotherapy

Ptcy Overcomes HLA Mismatch in Unrelated Donor Transplant for Acute Lymphoblastic Leukemia: A Study from the ALWP of the EBMT

Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation in First Remission: On Behalf of the EBMT Acute Leukemia Working Party

DNMT3A Mutations Deregulate the DNA Demethylation Pathway in Acute Myeloid Leukemia

Prognostic Impact of t(9;11) and Del(7q) As Intermediate-Risk Abnormalities in AML Following Allo-Transplant: Insights from the ELN 2022 Classification - an EBMT ALWP Study

Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMT

Mismatched Unrelated Donor Transplantation with Ptcy-Based Gvhd Prophylaxis Is Associated with Better Survival Than Double Unit Umbilical Cord Blood Transplantation in Patients with AML in First CR: A Study from the ALWP of the EBMT

Outcome of Allogeneic Stem Cell Transplantation in FLT3-TKD-Mutated AML - a Study on Behalf of the Acute Leukemia Working Party of the EBMT

Comparative Study for Haplo, MSD and MUD Allo-Hcts for AML Patients with KMT2A Rearrangement: A Study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Encouraging Outcome of AML with t(8;16) Following Allogeneic Stem Cell Transplantation in First Remission - a Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT

Outcome of Intensively Treated Elderly AML Patients Reported to the Harmony Alliance Compares Well to Outcome of Control Patients of the Prospective Randomized HOVON 103 Study in Elderly AML

CNS Prophylaxis in Adult ALL Patients after Stem Cell Transplantation: An EBMT Survey on General Practice

Should the European Leukemia Net 2022 Adverse Risk Classification of NPM1 mutated Acute Myeloid Leukemia be Revisited? Among Adverse Risk Cytogenetics, Solely Complex Karyotype Is Associated with Worse Post-Transplant Survival: A Study from the EBMT Acute Leukemia Working Party

Practice Patterns of Transplant Centers Regarding Maintenance Treatment Post Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia: A Survey on Behalf of the EBMT Acute Leukemia Working Party

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only